Intelligent bio solutions inc. reports fiscal 2023 third quarter financial results and operational highlights

- combined revenue and government support income increased 199% year-over-year - - sequential revenue growth of 28% - - filed 513(g) submission with u.s. fda for intelligent fingerprinting drug screening cartridge - - granted u.k. patent relating to dsr-plus cartridge reader - - completion of milestone 7, key phase of biosensor platform development - new york, may 11, 2023 (globe newswire) -- intelligent bio solutions inc. (“intelligent bio solutions,” “inbs” or the “company”) (nasdaq: inbs), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal third quarter ended march 31, 2023, and provided a business update. “inbs delivered revenue growth during the third quarter and achieved several important milestones in line with our regional expansion plans,” said harry simeonidis, chief executive officer at intelligent bio solutions.
INBS Ratings Summary
INBS Quant Ranking